CardioHub - CardioBites+ Amyloidosis-CardioBites Plus: Amyloidosis

CardioBites Plus: Amyloidosis - Treatment and Management

Video Transcription

Video Summary

This CardioBytes Plus episode discusses treatment and management of cardiac amyloidosis with experts Lily Stern and Lori Roth. Disease-modifying therapies target AL amyloidosis with chemotherapy and daratumumab, while ATTR amyloidosis treatments include TTR gene silencers, stabilizers, and emerging degraders. Three FDA-approved therapies for ATTR—two oral stabilizers (tafamidis, acoramidis) and the silencer vutricerin—slow disease progression. Heart failure management focuses on volume control with diuretics, SGLT2 inhibitors, MRAs, cautious use of digoxin, and limited use of beta blockers due to low blood pressure. Arrhythmia treatment includes rhythm control and anticoagulation. Selected patients may receive transplants; palliative care is important early on.

Keywords

cardiac amyloidosis

AL amyloidosis treatment

ATTR amyloidosis therapies

heart failure management

arrhythmia treatment